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Herpes simplex virus glycoprotein D is a component of the virion envelope and appears to be involved in attachment, 
penetration, and cell fusion. Monoclonal antibodies (MAbs) against this protein can be arranged in groups, on the basis 
of a number of biological and biochemical properties. Group I antibodies are type-common, have high complement- 
independent neutralization titers, recognize discontinuous (conformational) epitopes, and block each other in a binding 
assay. The sum of their epitopes constitutes antigenic site I of gD. Using a panel of neutralization-resistant mutants, 
we previously found that group I MAbs can be divided into two subgroups, la and lb, such that mutations selected with 
la antibodies have little or no effect on binding and neutralization by lb antibodies, and vice versa. Antigenic site I 
therefore consists of two parts, la and lb. We have now identified the point mutations which prevent neutralization. 
Two lb MAbs (DLl 1 and 4s) selected a Ser to Asn change at residue 140; this alteration creates a new N-linked 
glycosylation site, which is used. A third lb MAb (D2) selected a Gln to Leu change at 132. The mutation selected by 
the la MAb HDl (Ser to Asn at residue 216) is identical to that selected by MAb LP2, another la antibody. By using 
oligonucleotide-directed mutagenesis, we have produced gD genes with combinations of the above mutations. At- 
tempts to recombine these genes into the virus genome were unsuccessful, suggesting that the combinations are 
lethal. This was confirmed by a complementation assay which measures the ability of gD transiently expressed in 
transfected Vero cells to rescue the production of infectious virus by the gD-minus mutant F-SD@. o wgo Academic 
Press, Inc. 
INTRODUCTION 
Glycoprotein D (SD) of herpes simplex virus (HSV) is 
involved in virus infection and pathogenesis, induces 
humoral and cellular immune responses (Dix et al., 
1981; Eisenberg et a/., 1982; Heber-Katz et a/., 1985; 
Martin et al., 1987; Rouse and Lopez, 1984; Zarling et 
a/., 1986), and protects animals against a lethal virus 
challenge (Berman et al., 1985; Chan, 1983; Cohen et 
al., 1985; Cremer et al., 1985; Dix and Mills, 1985; 
Eisenberg et al., 1985; Lasky et al., 1984; Long et al., 
1984; Paoletti et a/., 1984). It is present on the surface 
of purified virions (Stannard et a/,, 1987), and appears 
to be essential for virus replication in tissue culture, in 
that mutants lacking gD can attach to, but not pene- 
trate, target cells (Johnson and Ligas, 1988; Ligas and 
Johnson, 1988). In addition, studies with monoclonal 
antibodies (MAbs) specific for gD have indicated possi- 
ble roles in adsorption (Fuller and Spear, 1985), pene- 
tration (Fuller and Spear, 1987; Highlander et al., 
1987), and cell fusion (Highlander et a/., 1987; Noble 
et al., 1983). We have previously arranged anti-gD 
MAbs in several groups, on the basis of various charac- 
’ To whom requests for reprints should be addressed. 
teristic properties (Eisenberg and Cohen, 1986; Eisen- 
berg et al., 1985; lsola et al., 1989; Muggeridge et al., 
1989). MAbs in groups II, V, VII, and XI recognize dena- 
tured gD and define continuous epitopes. Antibodies 
in groups I, III, IV, and VI recognize discontinuous epi- 
topes, and therefore bind only to native gD. Group I 
MAbs are type-common, have high complement-inde- 
pendent neutralization titers (Eisenberg et a/., 1982; 
Fuller and Spear, 1985; Kijmel et a/,, 1985; Minson et 
al., 1986; Pereira et a/., 1980; Showalter et a/., 1981), 
and inhibit penetration (Fuller and Spear, 1987; High- 
lander et a/., 1987); some are able to inhibit cell fusion 
by syncytial strains of HSV-1 (Highlander et a/., 1987; 
Noble et a/., 1983). 
We recently reported a detailed study of the relation- 
ships between seven group I MAbs (Muggeridge eta/., 
1988). Six of the antibodies blocked each other in a 
competitive binding assay with purified gD as the tar- 
get antigen, so their epitopes on gD are clustered to 
form an antigenic site (site I). Analysis of a panel of 
monoclonal antibody-resistant (i.e., neutralization-re- 
sistant) mar mutants showed, however, that the anti- 
bodies fall into two subgroups (la and lb). Mutants se- 
lected with la MAbs were still neutralized by lb MAbs, 
and vice versa. The two subgroups can also be distin- 
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guished by their reactivity with gD deletion mutants 
(Muggeridge et al., 1988). 
We have now used DNA sequencing to identify the 
changes responsible for resistance to neutralization, 
and the locations of these changes reveal a previously 
unrecognized part of antigenic site I, confirming its dis- 
continuous nature. In addition, one of the mutations 
creates a new consensus site for N-linked glycosyla- 
tion. We used oligonucleotide-directed mutagenesis to 
combine mar mutations within antigenic site I, and then 
studied the ability of these multiple mutants to func- 
tion, using recombination and complementation as- 
says. 
MATERIALS AND METHODS 
Cells and virus strains 
CVl and BHK cells were grown in Eagle’s MEM, sup- 
plemented with 5% fetal bovine serum (FBS). Vero and 
COS-1 cells were grown in Dulbecco’s modified MEM 
(DME) containing 5% FBS. VD60 cells were grown in 
DME containing 5% FBS and 1 mM histidinol (Ligas 
and Johnson, 1988). Isolation of the mar mutant viruses 
has been described previously (Highlander eta/., 1987; 
Minson eta/., 1986; Muggeridge eta/., 1988); MarD.4S 
was derived from the parent strain KOS, MarDLl 1 was 
derived from Patton, and MarD2.1 and MarD.HDl 
were derived from KOS32 1. Isolation of the gD-minus 
virus, F-gDp, has been described previously (Ligas and 
Johnson, 1988); F-gDP was propagated in VD60 cells. 
Antibodies 
The antibodies used in this study are listed in Table 
1. Of the group I MAbs, DLl 1 and D2 were isolated in 
the authors’ laboratories; HDl was kindly provided by 
Lenore Pereira, LP2 by Anthony Minson, and 4s by 
Martin Zweig. The other two group I MAbs, Ill-l 14-4 
and Ill-l 74-l (Para et al., 1985) were not used in this 
study. DL6 is a group II MAb that recognizes a continu- 
ous epitope of gD-1 (residues 272 to 279 of the mature 
protein) (Eisenberg et al., 1985; lsola et al., 1989). 1 D3 
(Friedman et al., 1984) and LP14 (Minson et a/., 1986) 
are group VII MAbs that recognize overlapping epi- 
topes within residues 1 to 23 (Bosch et a/., 1987; Dietz- 
schold et al., 1984). DL2 is a group VI MAb that recog- 
nizes a discontinuous epitope (Cohen et a/., 1986). RIP 
is a group III MAb that recognizes a discontinuous epi- 
tope (Seigneurin et al., 1983; lsola et al,, manuscript in 
preparation). 
Isolation of viral DNA and cloning of 
BamHl J fragments 
Total intracellular viral DNA was isolated from BHK 
cells infected with virus at 0.01 PFU per cell, essentially 
as described by Walboomers and Ter Schegget (1976). 
Centrifugation was for 16 hr at 50,000 rpm/20” in a 
Beckman 50Ti vertical rotor. The resulting band of vi- 
rion DNA was removed with a syringe, extracted with 
butanol to remove ethidium bromide, and dialyzed 
against 10 m/l/l Tris-HCI, pH 8.0, 1 mM EDTA. The 
DNA was digested with BarnHI and electrophoresed 
on a 0.8% agarose gel. Bands between 5 and 8 kb were 
electroeluted onto NA45 nitrocellulose, from which 
DNA was recovered by incubation in 20 mMTris-HCI, 
pH 7.5, 1 .O n/l NaCI, followed by phenol/chloroform ex- 
traction and ethanol precipitation. These fragments 
were then cloned into the BamHl site of pGEM 1, using 
standard techniques (Maniatis et al., 1982). Clones 
containing the BamHl J fragment were identified by hy- 
bridization of a gD riboprobe to Southern blots of plas- 
mid DNA. 
DNA sequencing and oligonucleotide-directed 
mutagenesis 
Double-stranded plasmid DNA was sequenced by 
the procedure of Chen and Seeburg (1985) using a set 
of oligonucleotide primers spaced at intervals along 
the gD gene. Mutagenesis of the gD gene cloned into 
the HindIll site of M13mp18 was performed by the 
method of Zoller and Smith (1982) as modified by Kun- 
kel (1987). The sequences of the oligonucleotides 
were Gln 132 to Leu, CAGCGGGGCAGCGTXGGA; 
Ser 140 to Asn, CGCTGAAGTTGTCATAGT; Ser 2 16 to 
Asn, ATCCCGATGTTGTCCACC; Ser 216 to Phe, 
GCATCCCGATGAAGTCCACCGTC. To create double 
and triple mutants, equimolar mixtures of the appropri- 
ate oligonucleotides were used. HindIll fragments con- 
taining mutated gD genes were excised from replica- 
tive-form phage DNA and inserted into pRSVnt EPA, 
a eukaryotic expression vector (Carswell et al., 1986). 
Construction of the analogous plasmid pRE4, which 
expresses wild-type gD (Patton strain), has been de- 
scribed previously (Cohen et al., 1988). 
Antigenic analysis of mutants 
Infection of CVl cells and transfection of COS-1 cells 
were performed by previously described methods (Gor- 
man et a/., 1982; Muggeridge et a/., 1988). Cytoplas- 
mic extracts were prepared from these cells (Mugger- 
idge et a/., 1988) and analyzed either by the native gel/ 
Western blot procedure (Cohen eta/., 1986) or on nitro- 
cellulose dot blots (Cohen et a/., 1984). 
Native gel electrophoresis and Western blotting 
The native polyacrylamide gel system and Western 
blotting procedure have been described previously 
(Cohen et al., 1986). All gels used in this study con- 
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tained 1 Oq/o acrylamide/O. 1% bis-acrylamide (separat- 
ing gel) and 5% acrylamide/0.3% bis-acrylamide 
(stacking gel). 
Endoglycosidase F (endo F) digestion and 
nitrocellulose dot blots 
Cytoplasmic extracts were incubated with endo F 
(Boehringer-Mannheim) for 15 min at 37” (0.05 units of 
enzyme per 15 ~1 of extract). Two-microliter samples 
were spotted onto nitrocellulose, then probed with 
MAbs followed by ‘251-Protein A (Cohen et al., 1984). 
Construction of a cassette vector for recombination 
of gD mutants into the virus genome 
Construction of the cassette vector pMM77 and its 
derivatives is outlined in Fig. 1. Plasmid pJB3 consists 
of a 3.6-kb Smal subclone of the HSV-1 BamHl J frag- 
ment (Betz eta/., 1983) cloned into pACYCl77 (Chang 
and Cohen, 1978); it includes the gD coding se- 
quences, together with 0.7 and 1.6 kb of the upstream 
and downstream flanking sequences, respectively. 
pUC18AHN was derived from pUC18 by digestion with 
HindIll and /Varl, followed by religation, which de- 
stroyed both sites. The Smal fragment from pJB3 was 
recloned into the Smal site of pUC18AHN to form 
pMM77. Since pMM77 has HindIll and Narl sites only 
within the viral insert, partial digestion with these en- 
zymes produced a 5.5-kb fragment and a I-kb frag- 
ment, the latter including the codons for amino acids 1 
to 287 of the mature gD protein. The 5.5-kb fragment 
was isolated and ligated to 1 -kb HindIll-Narl fragments 
from mutated gD genes. The resulting plasmids were 
named pMM82 (140 and 216 mutations) and pMM89 
(132, 140, and 216 mutations). 
Transfection and isolation of viral recombinants 
Freshly trypsinized Vero cells were transfected by 
the procedure of DeLuca et a/. (1985) with the excep- 
tion that the glycerol shock was omitted. One micro- 
gram of virion DNA was used, together with 1 pg of 
Smal-digested plasmid DNA (either pMM82 or 
pMM89), and 10 pg of salmon sperm DNA. Virus was 
harvested after 4 to 5 days, when CPE was wide- 
spread, and replated on CVl monolayers for screen- 
ing. Recombinants were identified by their reaction 
with MAbs in an immunoperoxidase (black plaque) as- 
say (Holland et al,, 1983; Kousoulas et al., 1984). 
lmmunoperoxidase assay 
This procedure is modified from that described by 
Holland et a/. (1983) and Kousoulas et a/. (1984). Cell 
monolayers were washed once with DME containing 
I 
1. Smal 1. SmaI 
2. Isolate 3.6 kb 2. Phamhatase 
I 3. 421. Narl Isolate Ligate Hind111 partial with 5.5 kb 1.0 fragment kb HindIll-Narl 
fragment from mutated gD gene 
N 
FIG. 1. Construction of cassette vector pMM77 and its derivatives. 
The 3.6-kb Sm.4 insert containing the gD gene was moved from pJB3 
to pUCAHN so that a HindllllNarl partial digest could be used to re- 
move most of the gD coding sequence. The resulting gap was filled 
with the corresponding 1 .O-kb HindllllNarl fragment from mutant gD 
plasmids; pMM82 contains the fragment from pMM76, and pMM89 
contains the fragment from pMM88 (see Results). S, Smal; H, HindIll; 
N. Narl. 
5% FBS, then incubated in DME containing 5% FBS 
and an appropriate MAb (1 to 1000 dilution) for 1 hr at 
room temperature (RT). After two washes with DME, 
the cells were incubated in DME containing 19/o FBS 
and 2 PI/ml protein A-peroxidase (Boehringer-Mann- 
heim) for 1 hr at RT. The cells were then washed once 
with DME and once with PBS, before incubation with 
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peroxidase substrate for 5 min at RT. The substrate 
was prepared by adding 5 ~1 of 30% H,O, and 5 mg of 
4-chloro-1-naphthol in 0.5 ml of ethanol to 50 ml 
of PBS. 
Complementation assay 
The procedure is derived from that used by Cai eta/. 
(1988) for the analysis of HSV glycoprotein B mutants. 
Sixty-millimeter petri dishes were seeded with 8 X 1 O5 
Vero cells, and transfected with DNA/calcium phos- 
phate precipitates the next day. Ten to 30 pg of plasmid 
DNA in 219 ~1 of dHZO was mixed with 31 ~1 of 2 M 
CaCI,, then added to 250 ~1 of 2x HBS (0.27 M NaCI, 
10 mn/l KCI, 1.4 mn/l NaH,PO,, 42 mM HEPES, pH 
7.08). After 15 min, the suspension was added to a 
subconfluent monolayer of Vero cells, which had been 
fed with fresh medium 1 hr previously. The cells were 
incubated at 37” for 5 hr, treated with 15% glycerol in 
HBS for 2 min at 37”, then washed once and incubated 
in DME/5% FBS for 16 hr at 37”. Each dish of cells was 
subsequently infected at RT with 1 O6 PFU of F-gDP vi- 
rus in 0.25 ml of tricine-buffered saline (TBS) (Cai eta/., 
1988) followed by the addition of 5 ml of DME/5% FBS 
and incubation for 1 hr at 37”. The medium was then 
removed, and extracellular virus was inactivated by in- 
cubating the monolayer for 1 min in glycine-saline, pH 
3.0 (Cai eta/., 1988) followed by two washes with TBS. 
After 24 hr in DME/5% FBS at 37”, the cells were lysed 
by Dounce homogenization; nuclei were pelleted by 
low-speed centrifugation, and the supernatant was 
stored at -70” for subsequent determination of virus 
titers on VD60 cells. One hundred percent comple- 
mentation is defined as the titer obtained after transfec- 
tion with plasmid pRE4, which expresses wild-type gD. 
Complementation with a mutant is then defined by the 
formula 
O/O complementation = 
1 o. x 
( 
titer with mutant plasmid - titer with no DNA 
titer with pRE4 - titer with no DNA 1 ’ 
RESULTS 
Cloning and sequencing of mutant gD genes 
The gD gene is contained within the 6.5-kb BamHl J 
fragment of HSV-1 (Lee eta/., 1982). This fragment was 
isolated from mutant virion DNAs and cloned into 
pGEM1, as described under Materials and Methods. 
The plasmids were designated pMM72 (MarD2.1) 
pTW83 (MarDLl l), and pTW84 (MarD.HDl). pMar62, 
a,plasmid containing the MarD.4S BarnHI J fragment 
cloned into pBR325, was provided by Randal Byrn. 
The entire ectodomain of the MarD.4S gD gene was 
sequenced. As the sequence of gD from its parent 
strain (KOS) has not been reported, we compared 
MarD.4S to the wild-type Patton strain (Watson et al., 
1982). The only difference was at residue 140, where 
MarD.4S has an Asn and Patton has a Ser (Fig. 2). This 
difference is responsible for the resistance of MarD.4S 
to neutralization by MAb 4S, as confirmed by site-di- 
rected mutagenesis (see below). Since KOS, like Pat- 
ton, is neutralized by 4S, it does not have an Asn at 
140. The other three mutants were selectively se- 
quenced (Fig. 2). MarDLl 1, which behaves identically 
to MarD.4S in neutralization and binding assays, has 
the same mutation. MarD2.1, the third mutant selected 
with a lb MAb, has a Gln to Leu substitution at amino 
acid 132. The la mutant, MarD.HDl , has a Ser 216 to 
Asn change, the same as that previously reported for 
a mutant selected with LP2, another group la MAb 
(Minson et a/., 1986). 
Confirmation of mutant phenotypes by 
site-directed mutagenesis 
Each of the three mutations identified by sequencing 
was reproduced individually in a Patton gD gene 
cloned into Ml 3mpl8. This was accomplished by oli- 
gonucleotide-directed mutagenesis, using the proce- 
dure of Kunkel(l987). HindIll fragments containing the 
mutated gD genes were then excised from double- 
stranded phage DNA and cloned into the expression 
vector pRSVnt EPA (Carswell et a/., 1986). Plasmids 
pMM80, pMM85, and pMM87 have mutations in the 
codons for amino acids 140, 132, and 216, respec- 
tively. The corresponding mutant proteins were ex- 
pressed in transfected COS-1 cells, and their antige- 
nicity tested with the appropriate MAbs (Table 1). Cell 
extracts were electrophoresed on native (nondenatur- 
ing) gels, transferred to nitrocellulose, then probed with 
a MAb followed by ‘251-Protein A. The results (Fig. 3) 
confirm that the mutations at residues 132, 140, and 
216 are responsible for the altered antigenicity of the 
respective mar mutants. The reactions of each MAb 
with wild-type gD expressed by plasmid pRE4 are 
shown in lanes 1,3,5,7, and 9. The 216 mutation abol- 
ished binding of LP2 (Fig. 3, lane 4) but not HDl (Fig. 
3, lane 2) as previously shown for the interaction of 
these MAbs with gD from the MarD.LP2 and 
MarD.HDl viruses (Muggeridge et a/., 1988). The 140 
mutation abolished binding of DLl 1 (Fig. 3, lane 6) and 
4s (Fig. 3, lane 8), and the 132 mutation abolished 
binding of D2 (Fig. 3, lane 10). 
One explanation for the failure of HDl to neutralize 
MarD.HDl and MarD.LP2 even though it can still bind 
is that the orientation of bound antibody is changed in 
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CAG->CTG AGC->AAC 
'132' '140' 150 
RMGGNCAIPITVMEYTECSYNKSLGACPIRTQPRWNYYDSFSAVSEDNLG Patton 
............................... L .................. MarD2.1 
....................................... N .......... MarDLll 




. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . MarD2.1 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . MarDLll 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . MarDAS 





. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . MarD2.1 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . MarDLll 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . MarD.4S 
. . . . . . . . . . . . . . . N . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . MarD.HDl 
FIG. 2. Amino acid changes in gD-1 mar mutants. The sequence shown is that of the Patton strain, from residues 101 to 250 of the mature 
protein. Below 11 are the single amino acid substitutions identified in the four mar mutants, with the corresponding codons shown above. 
such a way that it no longer blocks the participation of 
gD in penetration. Alternatively, amino acid 216 might 
itself be outside of the HDl epitope but be able to in- 
fluence whether neutralization occurs as a conse- 
quence of antibody binding. If the former possibility 
was correct, then changing 216 to a residue other than 
Asn might abolish binding of HDl. We therefore used 
oligonucleotide-directed mutagenesis to change 216 
from Ser to Phe. The resulting protein was expressed 
in transfected COS-1 cells and analyzed by the native 
gel/Western blot procedure (Fig. 4). As expected, the 
TABLE1 
ANTI-SD MONOCLONALANSIBODIES USED IN THIS STUDY” 
MAb group MAb Epitope 
II DL6 Continuous: 272-279 
VII 1 D3, LP14 Continuous: l-23 
la HDl, LP2 Discontinuous: l-233 
lb DLl 114s. D2 Discontinuous: l-275 
Ill RIP Discontinuous: l-233 
VI DL2 Discontinuous: l-233 
a See Muggeridge eta/. (1989) for review 
mutation had no effect on binding of lb MAbs (Fig. 4, 
lanes 6, 8, and 10) or nongroup I MAbs (Fig. 4, lanes 
12, 14, and 16). However, binding of both the la MAbs 
was abolished (Fig. 4, lanes 2 and 4), indicating that 
residue 216 lies within the epitopes of HDl and LP2. 
The Serl40 to Asn mutation creates a new 
N-linked glycosylation site 
The consensus sequence for attachment of N-linked 
carbohydrate chains is Asn-X-SerTThr, where X can 
be any amino acid except Pro (Mononen and Karja- 
lainen, 1984; Roitsch and Lehle, 1989). gD has three 
of these sequences, with the Asn residues at positions 
94, 121, and 262; all three are used (Matthews et a/., 
1983). Residues 141 and 142 of gD are Phe-Ser, so 
the conversion of residue 140 to Asn in MarD.4S and 
MarDLl 1 creates a new consensus sequence. To test 
for glycosylation at this site, we compared the electro- 
phoretic mobilities of the wild-type and mutant pro- 
teins, before and after enzymatic removal of N-linked 
carbohydrates (Fig. 5). Cytoplasmic extracts of in- 
fected CVl cells were incubated for 15 min at 37” with 
endo F; mock digests were performed with no enzyme. 
The samples were then electrophoresed on a native 
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FIG. 3. Reaction of MAbs with gD containmg site-drrected mutations correspondrng to those identified by sequencing. Cytoplasmic extracts 
of COS-1 cells transfected wrth plasmids expressing gD mutants were electrophoresed on native polyacrylamide gels, transferred to nitrocellu- 
lose, and probed with one of the group I MAbs followed by ‘?Protein A. Lanes 1, 3, 5. 7, and 9: plasmid pRE4, which expresses wild-type 
(Patton) gD. Lanes 2 and 4: plasmid pMM87, which has a mutation at 216. Lanes 6 and 8: plasmtd pMM80, which has a mutation at 140. Lane 
10: plasmid pMM85, which has a mutation at 132. Lanes 1 and 2 were probed with HDl; lanes 3 and 4 were probed with LP2; lanes 5 and 6 
were probed with DLl 1; lanes 7 and 8 were probed with 4s; lanes 9 and 10 were probed with D2. 
gel, Western blotted, and probed with DL6 (an anti-gD 
MAb that recognizes a continuous epitope; see Table 
1) followed by lz51-Protein A. Mock-digested gD from 
the two mutants (Fig. 5, lanes 2 and 3) had a lower 
mobility than wild-type KOS gD (Fig. 5, lane 1). After 
deglycosylation, the mutant (Fig. 5, lanes 5 and 6) and 
wild-type (Fig. 5, lane 4) proteins had identical mobili- 
ties. The extra glycosylation site created by the muta- 
tion at amino acid 140 is therefore used in both mu- 
tants. 
Antigenic site lb is partially covered by a 
carbohydrate chain in the MarD.4S 
and MarDLl 1 mutants 
These two mutants are resistant to neutralization by 
the lb MAbs 4S, DLl 1, and D2. It seemed likelythat the 
loss of antibody recognition was caused by covering of 
the lb site by the new carbohydrate chain. To test this 
possibility, we compared antibody binding before and 
after deglycosylation. Initially, cytoplasmic extracts of 
12 34 5 6 7 8 9 10 11 12 13 14 15 16 
infected cells were digested with endo F, or mock-di- 
gested, for 15 min at 37”, then electrophoresed on na- 
tive gels, Western blotted, and probed with MAbs fol- 
lowed by ‘z51-Protein A. However, we found significant 
loss of conformation of deglycosylated wild-type KOS 
gD, such that binding of MAbs recognizing discontinu- 
ous epitopes was reduced (Fig. 6). Any specific effect 
of deglycosylation on site lb could therefore not be 
evaluated. To determine whether loss of conformation 
was occurring during the endo F incubation or during 
subsequent electrophoresis and blotting, the effect of 
longer incubation times was investigated. If denatur- 
ation was occurring during the endo F incubation, then 
binding of MAbs with discontinuous epitopes, such as 
HDl , should eventually be reduced to zero. Samples 
were taken from endo F and mock digests at 15 min, 
30 min, 1 hr, and 2 hr, and two identical native gels 
were run (Fig. 7). One was probed with DL6, which re- 
acts with denatured and native gD, the other with HDl 
DL6 reacted similarly with all mock-digested (Fig. 7A, 
FIG. 4. Reaction of MAbs with gD containing a site-directed mutation of Ser 216 to Phe. Cytoplasmic extracts of transfected COS-1 cells were 
electrophoresed on native polyacrylamide gels with no comb and Western blotted. The nitrocellulose blots were cut into strips, which were 
probed with a MAb followed by “‘I-Protein A, then arranged in pairs for autoradiography. Lanes 1, 3, 5, 7, 9, 1 1, 13, and 15: plasmid pRE4, 
which expresses wild-type (Patton) gD. Lanes 2, 4. 6, 8. 10. 12, 14, and 16: plasmid pD1 S216F, which expresses gD with a Ser 2 16 to Phe 
mutation. Lanes 1 and 2 were probed with HDl ; lanes 3 and 4 were probed with LP2; lanes 5 and 6 were probed with DLl 1; lanes 7 and 8 
were probed with 45; lanes 9 and 10 were probed with D2; lanes 11 and 12 were probed with the group VI MAb DL2; lanes 13 and 14 were 
probed with the group III MAb RIP; lanes 15 and 16 were probed with the group II MAb DL6. 
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FIG. 5. Endo F drgestion of gD. CVl cells were infected with the 
wild-type KOS strain, or with the MarD.4S or MarDLl 1 mutants. Cy- 
toplasmic extracts were incubated at 37” for 15 min, with or without 
the addition of endo F, then electrophoresed on native polyacry- 
amrde gels, transferred to nitrocellulose, and probed with MAb DL6, 
followed by ‘ZSI-Protein A. Lanes 1 and 4: KOS. Lanes 2 and 5: 
MarD.4S. Lanes 3 and 6: MarDLl 1. Lanes 1,2, and 3: mockdigests. 
Lanes 4. 5, and 6: endo F digests. 
lanes 1 to 4) and endo F-digested (Fig. 7A, lanes 5 to 
8) samples. The reaction of HDl with endo F-digested 
samples (Fig. 7B, lanes 5 to 8) was weaker than with 
mock-digested samples (Fig. 7B, lanes 1 to 4), as ex- 
pected. However, there was no progressive loss of 
binding with increasing digestion time. The loss of con- 
formation caused by deglycosylation of gD is therefore 
manifest during native gel electrophoresis and Western 
blotting, rather than during the 37” incubation with 
endo F. 
As an alternative to native gels, we turned to nitrocel- 
lulose dot blots. As before, cytoplasmic extracts of 
cells infected with MarD.4S or KOS virus were digested 
with endo F or mock-digested. To confirm that the car- 
bohydrate chains had indeed been removed by endo F, 
aliquots were run on gels, Western blotted, and probed 
with DL6 (data not shown). For the dot blots, ~-PI ali- 
quots of the digested extracts were spotted on nitro- 
cellulose, then probed with a MAb followed by ‘251-Pro- 
12 3 4 5 6 7 8 9 10 
FIG. 6. Effect of N-linked carbohydrate removal on discontinuous 
epitopes of gD. A cytoplasmic extract of CVl cells infected with KOS 
virus was incubated at 37” for 15 min, with or without the addition of 
endo F, then electrophoresed on native polyacrylamide gels, trans- 
ferred to nitrocellulose, and probed with MAbs followed by ‘?Pro- 
tein A. Lanes 1, 3, 5, 7, and 9: mock digests. Lanes 2, 4, 6, 8, and 
10: endo F digests. Lanes 1 and 2 were probed with HDl ; lanes 3 
and 4 were probed with DLl 1; lanes 5 and 6 were probed with 4% 
lanes 7 and 8 were probed with D2; lanes 9 and 10 were probed with 
DL2 (group VI). 
A B 
1234 5678 1234 5678 
FIG. 7. Effect of endo F on stability of gD. A cytoplasmic extract of 
CVl cells infected with KOS virus was incubated at 37”. with or with- 
out the addition of endo F. Samples were removed at various times 
for electrophoresis on native polyacrylamide gels, transfer to nitro- 
cellulose, and analysis with MAbs followed by ‘*‘I-Protein A. (A) 
Probed with DL6. (6) Probed with HDl. Lanes 1 to 4 of A and B are 
mock digests; lanes 5 to 8 of A and B are endo F digests. The diges- 
tion times were as follows: lanes 1 and 5, 15 min; lanes 2 and 6. 30 
min; lanes 3 and 7, 1 hr; lanes 4 and 8, 2 hr. 
tein A (Fig. 8). Four identical sets of spots were made; 
as a control to show that equal amounts of gD were 
present in each extract, one set was probed with DL6, 
which reacts equally with wild-type and mutant gD and 
is not affected by carbohydrate removal. The other 
three sets were probed with 4S, DLl 1, and D2. Binding 
of DLl1 and D2 was partially recovered after endo F 
digestion, indicating that their epitopes are indeed 
blocked by carbohydrate. However, 4s failed to bind to 
MarD.4S gD after digestion. After carbohydrate re- 
moval, the only difference between the mutant and the 




FIG. 8. Effect of N-linked carbohydrate removal on binding of lb 
MAbs. CVl cells were infected either wrth the wild-type KOS strain 
or with the MarD.4S mutant. Cytoplasmic extracts were incubated 
at 37” for 15 min, with or without the addition of endo F. and 2-@I 
aliquots were then spotted on nitrocellulose and probed with a MAb 
followed by ‘251-Protein A. One set of samples was probed with the 
group II MAb DL6; the otherthree sets were probed with the lb MAbs 
DLl 1, D2, and 4s. 
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FIG. 9. Reaction of MAbs with gD contarnrng multiple site-directed mutations within antrgenrc site I. Cytoplasmic extracts of COS-1 cells 
transfected with plasmids expressing gD mutants were electrophoresed on native polyacrylamide gels, transferred to nrtrocellulose, and probed 
with a MAb followed by ‘*51-Protein A. Lanes 1, 4, 7, 10. 13. and 16: plasmid pRE4, whrch expresses wild-type (Patton) gD. Lanes 2, 5, 8, 1 1, 
14, and 17: plasmid pMM76, which has mutations at 140 and 216. Lanes 3, 6, 9, 12, 15, and 18: plasmid pMM88, which has mutations at 
132, 140, and 216. Lanes 1, 2, and 3 were probed with DL6; lanes 4, 5, and 6 were probed wrth HDl ; lanes 7, 8, and 9 were probed with LP2; 
lanes 10, 11, and 12 were probed with DLl 1; lanes 13, 14. and 15 were probed with 4s; lanes 16, 17, and 18 were probed with D2. 
wild-type is the amino acid at 140. Therefore, Asn 140 
must be part of the antigenic site and not just an attach- 
ment point for carbohydrate. 
Construction of multiple mar mutants 
Since group I MAbs inhibit virus penetration and 
cell-cell fusion (Fuller and Spear, 1987; Highlander et 
a/., 1987; Noble et al., 1983) it is likely that antigenic 
site I overlaps a functionally important region of gD. In 
that case, it may be possible to alter the structure of 
site I in such a way that the protein can no longer func- 
tion. Since the individual mar mutations are found in 
viable viruses, the structural changes they cause are 
able to affect antibody binding but not gD function. 
However, a combination of these mutations may be 
sufficient to do both. To test this possibility, we used 
mixtures of mismatched oligonucleotides to create gD 
genes carrying two (140 and 216) or three (132, 140 
and 216) mutations. The mutated genes were cloned 
into pRSVnt EPA (Carswell et a/., 1986) to form plas- 
mids pMM76 (double mutant) and pMM88 (triple mu- 
tant). The corresponding proteins were expressed in 
transfected COS-1 cells, and their antigenicity ana- 
lyzed by the native gel/Western blot procedure (Fig. 9). 
The reactions of each MAb with wild-type gD ex- 
pressed by plasmid pRE4 are shown in lanes 1, 4, 7, 
10, 13, and 16. Both mutants reacted with DL6 (Fig. 
9, lanes 2 and 3). As expected, both mutants showed 
reduced or negligible binding with the lb MAbs DLl 1 
(Fig. 9, lanes 1 1 and 12) 4s (Fig. 9, lanes 14 and 15), 
and D2 (Fig. 9, lanes 17 and 18). Residual binding of 
D2 to the double mutant (Fig. 9, lane 17) was probably 
caused by incomplete glycosylation at amino acid 140. 
Neither mutant reacted significantly with the la MAbs 
(Fig. 9, lanes 5, 6, 8, and 9) even though HDl reacts 
well with the three single mutants (Muggeridge et a/., 
1988). Combining mutations at different residues 
within antigenic site I therefore has unpredictable 
effects on antigenicity. 
Recombination of multiple mar mutants 
into the virus genome 
If gD with two or three mutations within antigenic site 
I is functional, it should be possible to isolate viable 
viruses after recombining the genes into the virus ge- 
nome. We attempted to do this by cotransfection of 
Vero cells with viral and plasmid DNA. To increase the 
frequency of recombination, we first recloned the mu- 
tant gD genes from pMM76 and pMM88 into a cas- 
sette vector containing viral sequences normally found 
on either side of the gD gene, as described under Ma- 
terials and Methods. The resulting plasmids were 
named pMM82 (140 and 216 mutations) and pMM89 
(132, 140 and 216 mutations). To facilitate the screen- 
ing process, virion DNA was from MarD.LP14, a mar 
mutant that does not bind group VII MAbs, such as 
1 D3, owing to an Arg to His change at residue 16 (Min- 
son et a/., 1986). The gD gene in pMM82 and pMM89 
is wild-type at residue 16, and so rescues binding of 
lD3 to plaques formed by recombinants. Virus har- 
vested from the transfected Vero cells was plated on 
CVl cells, and the plaques were screened for binding 
of 1 D3 in a black plaque assay (Holland e2 a/., 1983; 
Kousoulas et al., 1984). Recombinant plaques were 
cloned twice, then tested for resistance to neutraliza- 
tion by group I MAbs (Muggeridge et al., 1988). Of two 
independent recombinants obtained with pMM82, 
both were resistant to LP2 but not DLl 1. Of nine inde- 
pendent recombinants obtained with pMM89, all were 
resistant to LP2, but not to DLl 1 or D2. These results 
suggested that the 216 mutation had been transferred, 
and that the 132 and 140 mutations had not. This was 
confirmed by cloning the BamHl J fragments from one 
pMM82 recombinant and one pMM89 recombinant, 
followed by sequencing of the appropriate sections of 
their gD genes. Both had the Ser216 to Asn mutation, 
but were wild-type at positions 132 and 140. Loss of 
these mutations suggested that the combination of la 
and lb mar mutations is lethal to the virus, presumably 
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TABLE 2 
COMPLEMENTATION OF F-gDPVws svgD MUTANT PLASMIDS 
Plasmid Mutation 
pMM80 Serl40 to Asn 
pMM85 Glnl32 to Leu 
pMM87 Ser2 16 to Asn 
pMM76 140+216 
pMM88 132+140+216 









because it prevents gD from carrying out its essential 
function. 
Complementation of a gD-minus virus by 
plasmid-encoded gD mutants 
F-gDP is a mutant virus that was derived from HSV- 
1 (strain F) by replacement of the gD coding sequence, 
and part of the gl gene, with DNA coding for Esche- 
richia co/i fl-galactosidase (Ligas and Johnson, 1988). 
It can replicate in VD60 cells, which contain an inte- 
grated copy of the gD gene, but not in Vero cells, from 
which the VD60 line was derived. Vero cells infected 
with F-gDP produce noninfectious virions lacking gD. 
Following a procedure used to analyze gB linker inser- 
tion mutants (Cai et a/., 1988) we have developed an 
assay in which gD transiently expressed from trans- 
fected plasmids is tested for its ability to rescue the 
production of infectious F-gDP in Vero cells. Vero cells 
are first transfected with an expression vector contain- 
ing a wild-type or mutant gD gene, then, on the next 
day, infected with F-gDP. On the third day, virus is har- 
vested and titered on VD60 monolayers. Titers ob- 
tained from Vero cells transfected with plasmid pRE4, 
which expresses wild-type gD-1, were 50- to 1 OO-fold 
higher than those from cells transfected with calcium 
phosphate alone or with plasmid pCD64, which ex- 
presses gC-2 (Seidel-Dugan et a/., submitted for publi- 
cation). 
Approximately 5% of Vero cells transfected with 10 
pg of pRE4 DNA showed surface expression of gD (de- 
tected by immunoperoxidase staining). Quantities of 
mutant plasmid DNA were adjusted to produce a sim- 
ilar percentage of expressing cells. Complementation 
results obtained with the gD mutants are shown in Ta- 
ble 2, each value representing the average of three 
independent experiments. Complementation with 
pMM85 and pMM87, which have single mutations at 
132 and 216, respectively, was similar to that with 
pRE4. Complementation with pMM80, which has a 
mutation at 140, was reduced to 33%, which may be 
close to the lower limit for viability of a virus carrying 
this mutation. However, complementation by the mu- 
tants with two changes (pMM76) or three changes 
(pMM88) was much lower (between 4 and 8%) con- 
firming that these combinations of mutations within an- 
tigenic site I of gD are detrimental to its function. 
DISCUSSION 
MAbs which bind to antigenic site I of gD prevent 
virus penetration into the cell (Fuller and Spear, 1987; 
Highlander et al., 1987) block cell fusion (Campadelli- 
Fiume et al., 1988b; Highlander et al., 1987; Noble et 
a/., 1983) and have high complement-independent 
neutralization titers (Eisenberg et al., 1982; Fuller and 
Spear, 1985; Ktimel et al., 1985; Minson et a/., 1986; 
Pereira et al., 1980; Showalter et al., 1981). Because 
this site, or an adjacent region, is vital for the proper 
functioning of gD during infection, we have begun to 
map it in detail. 
Previously, we have precisely mapped several con- 
tinuous antigenic sites of gD, using synthetic peptides 
(Cohen eta/., 1984; Dietzschold eta/., 1984; Eisenberg 
et al., 1985). Site I, being discontinuous, cannot be 
mapped in this way. Instead, we have used a combina- 
tion of two approaches. First, group I MAbs were used 
to select neutralization-resistant mutant viruses for se- 
quence analysis (Highlander eta/., 1987; Minson eta/., 
1986; Muggeridge et al., 1988). Prior to sequencing, 
we tested the panel of mar mutants for reactivity with 
all seven group I MAbs, and were able to divide the site 
into parts la and lb, recognized by two MAbs and five 
MAbs, respectively. Second, a series of gD truncation 
and deletion mutants was created (Cohen et a/., 1988) 
and the corresponding proteins were expressed in 
transfected cells. Their analysis indicated that site la 
is contained within residues 1 to 233, whereas site lb 
requires residues between 234 and 275 (Muggeridge 
et al., 1988). 
We have now used DNA sequencing and oligo- 
nucleotide-directed mutagenesis to identify the altered 
amino acids in the mar mutants. The la mutant 
(MarD.HDl) has a change at 216, which is consistent 
with the truncation mutant data. The mutation is identi- 
cal to that in MarD.LP2, a mutant selected with another 
la MAb (Minson et al., 1986). We anticipated that the 
lb mutants would have changes between 234 and 275, 
but that was not the case. Instead, the mutations were 
at 132 (MarD2.1) and 140 (MarDLl 1 and MarD.4S), 
emphasizing the discontinuous nature of the antigenic 
site. The change at 140 creates a new consensus se- 
quence for attachment of an N-linked oligosaccharide; 
this is not uncommon in mar mutants of other viruses 
(Caust et al., 1987; Skehel et al., 1984; Vrati et al., 
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1988). Removal of oligosaccharides by endo F diges- 
tion restored binding of two lb MAbs, but not a third. 
Some lb MAbs are therefore sensitive to the amino acid 
at 140, which is Ser in wild-type gD but Asp in the endo 
F-treated mutants. In the course of the endo F analysis, 
we also discovered that removal of N-linked oligosac- 
charides from gD leaves the protein more susceptible 
to denaturation during electrophoresis in low-SDS na- 
tive acrylamide gels and/or Western blotting. 
A computer analysis of the gD sequence (Eisenberg 
et a/., 1985) predicted that amino acids 132 to 140 lie 
within a hydrophilic sequence which is a candidate for 
an antigenic site (Hopp and Woods, 1981). However, 
peptides corresponding to amino acids 124 to 136 and 
130 to 139 were not recognized by rabbit antisera pre- 
pared against native gD (Isola eT al., 1989) so this re- 
gion probably does not form a continuous antigenic 
site. It therefore seems likely that folding of the protein 
brings amino acids 132 to 140 close to 234 to 275 in 
the native protein to form discontinuous site lb. 
The repeated isolation of a limited number of mu- 
tants is striking. Thus, a Ser to Asn change at 140 was 
selected by two lb MAbs, and a Ser to Asn change at 
2 16 was selected by two la MAbs (Minson eta/., 1986). 
In addition, the 216 change was selected by MAb LP2 
in two strains of HSV-1 and one of HSV-2 (Minson et 
a/., 1986). This may reflect a limited potential for non- 
deleterious amino acid substitutions within antigenic 
site I of gD, or indeed for the whole protein, given the 
near identity of known gD-1 sequences and 85% ho- 
mology between gD-1 and gD-2 (McGeoch et a/., 
1985; Minson et a/., 1986; Watson, 1983; Watson et 
a/., 1982). There is a marked contrast to the influenza 
HA and NA proteins, for example, which yield a variety 
of mutants when grown in the presence of a neutraliz- 
ing MAb (Daniels et a/., 1987; Webster et al., 1987). 
Each of the three mutations within site I occurs indi- 
vidually in a viable mutant virus. To determine whether 
antigenically intact site I is critical for virus infectivity, 
we have used oligonucleotide-directed mutagenesis to 
combine la and lb mutations in a cloned gD gene. A 
combination of two mar mutations in gB was previously 
shown to produce a temperature-sensitive phenotype 
in the virus (Marlin et a/., 1986). A similar study with gD 
(Highlander et a/., 1987) did not produce temperature- 
sensitive or lethal combinations; however, the mar mu- 
tations were from different antigenic sites. In this case, 
we have combined mutations within an antigenic site. 
The effect on antigenicity was greater than predicted 
by the properties of the individual mutations: the 132/ 
1407216 triple mutant (pMM88) showed negligible 
binding with all group I MAbs, including HDl, which 
binds to all three single mutants. Binding of MAbs that 
recognize discontinuous antigenic site III was not di- 
minished, and the mutant proteins were transported to 
the cell surface (data not shown), so their folding was 
not grossly altered. To determine if the loss of site la 
and lb antigenicity is correlated with loss of gD func- 
tion, we attempted to recombine the mutant genes into 
the virus genome. The recipient genome was from 
MarD.LP14, an HSV-1 mutant that fails to bind group 
VII MAbs, such as LP14 and 103, because of an Arg 
to His change at residue 16 of gD (Minson eta/., 1986). 
This facilitated the screening assay, because only re- 
combinants could bind 1 D3 in a black plaque assay. 
The recombinants were resistant to neutralization by 
LP2, and DNA sequencing confirmed that the mutation 
at residue 216 had been transferred to the virus ge- 
nome, but they remained sensitive to DLl 1 and D2. 
Sequencing showed that the recombinants still had the 
wild-type residues at 132 and 140. Therefore, of the 
four amino acid substitutions, only the two outermost 
(16 and 2 16) were transferred. One explanation is that 
the combination of mutations within sites la and lb is 
lethal, and that a complex crossover event must occur 
during recombination to remove the 132 and 140 mu- 
tations and generate a functional protein. 
To test the function of gD mutants, we used a com- 
plementation assay, in which gD transiently expressed 
by a plasmid can rescue the production of infectious 
virions by F-gDP, a mutant lacking a gD gene. A stock 
of F-gDp virus was grown in VD60 cells, which synthe- 
size gD from an integrated copy of the gene, passaged 
through Vero cells, which do not produce gD, and then 
titered on VD6Os. Vero cells previously transfected 
with plasmid pRE4, which expresses wild-type gD, pro- 
duced 50- to lOO-fold higher titers than cells trans- 
fected with calcium phosphate alone. It has been dem- 
onstrated recently that cells expressing large amounts 
of gD are resistant to infection by HSV-1 (Campadelli- 
Fiume et al., 1988a; Johnson and Spear, 1989); evi- 
dently our expression vector does not produce suffi- 
cient gD for this to be a problem. As expected, none of 
the three mar mutations individually prevented comple- 
mentation, although the mutation at 140 reduced com- 
plementation approximately 3-fold. However, the com- 
bination of two (140 and 216) or three (132, 140, and 
216) mutations within site I reduced the complementa- 
tion to low levels. These combinations of mutations, 
which cause no apparent structural changes beyond 
site I, therefore prevent gD from performing its essen- 
tial function in HSV replication. This assay is applicable 
to any gD mutant which can be expressed in trans- 
fected cells, and can be used to construct a functional 
map of the gD protein. 
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